363 related articles for article (PubMed ID: 31393852)
1. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.
Corbit KC; Wilson CG; Lowe D; Tran JL; Vera NB; Clasquin M; Mattis AN; Weiss EJ
JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393852
[TBL] [Abstract][Full Text] [Related]
2. Adipocyte JAK2 Regulates Hepatic Insulin Sensitivity Independently of Body Composition, Liver Lipid Content, and Hepatic Insulin Signaling.
Corbit KC; Camporez JPG; Edmunds LR; Tran JL; Vera NB; Erion DM; Deo RC; Perry RJ; Shulman GI; Jurczak MJ; Weiss EJ
Diabetes; 2018 Feb; 67(2):208-221. PubMed ID: 29203511
[TBL] [Abstract][Full Text] [Related]
3. Disruption of JAK2 in adipocytes impairs lipolysis and improves fatty liver in mice with elevated GH.
Nordstrom SM; Tran JL; Sos BC; Wagner KU; Weiss EJ
Mol Endocrinol; 2013 Aug; 27(8):1333-42. PubMed ID: 23782652
[TBL] [Abstract][Full Text] [Related]
4. Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
Shi SY; Luk CT; Schroer SA; Kim MJ; Dodington DW; Sivasubramaniyam T; Lin L; Cai EP; Lu SY; Wagner KU; Bazinet RP; Woo M
J Biol Chem; 2017 Mar; 292(9):3789-3799. PubMed ID: 28100771
[TBL] [Abstract][Full Text] [Related]
5. Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression.
Kaltenecker D; Themanns M; Mueller KM; Spirk K; Suske T; Merkel O; Kenner L; Luís A; Kozlov A; Haybaeck J; Müller M; Han X; Moriggl R
Cytokine; 2019 Dec; 124():154569. PubMed ID: 30389231
[TBL] [Abstract][Full Text] [Related]
6. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
7. Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance.
Corbit KC; Camporez JPG; Tran JL; Wilson CG; Lowe DA; Nordstrom SM; Ganeshan K; Perry RJ; Shulman GI; Jurczak MJ; Weiss EJ
JCI Insight; 2017 Feb; 2(3):e91001. PubMed ID: 28194444
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
9. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
[TBL] [Abstract][Full Text] [Related]
10. NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition.
Vesting AJ; Jais A; Klemm P; Steuernagel L; Wienand P; Fog-Tonnesen M; Hvid H; Schumacher AL; Kukat C; Nolte H; Georgomanolis T; Altmüller J; Pasparakis M; Schmidt A; Krüger M; Supprian MS; Waisman A; Straub BK; Raschzok N; Bernier M; Birkenfeld AL; Hövelmeyer N; Brüning JC; Wunderlich FT
Mol Metab; 2022 Dec; 66():101626. PubMed ID: 36356831
[TBL] [Abstract][Full Text] [Related]
11. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer.
Friedbichler K; Themanns M; Mueller KM; Schlederer M; Kornfeld JW; Terracciano LM; Kozlov AV; Haindl S; Kenner L; Kolbe T; Mueller M; Snibson KJ; Heim MH; Moriggl R
Hepatology; 2012 Mar; 55(3):941-52. PubMed ID: 22031092
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of reduced growth hormone action in fatty liver disease.
Rufinatscha K; Ress C; Folie S; Haas S; Salzmann K; Moser P; Dobner J; Weiss G; Iruzubieta P; Arias-Loste MT; Crespo J; Tilg H; Kaser S
Hepatol Int; 2018 Sep; 12(5):474-481. PubMed ID: 30206761
[TBL] [Abstract][Full Text] [Related]
13. Adult-Onset Hepatocyte GH Resistance Promotes NASH in Male Mice, Without Severe Systemic Metabolic Dysfunction.
Cordoba-Chacon J; Sarmento-Cabral A; Del Rio-Moreno M; Diaz-Ruiz A; Subbaiah PV; Kineman RD
Endocrinology; 2018 Nov; 159(11):3761-3774. PubMed ID: 30295789
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
15. Lack of FGF21 promotes NASH-HCC transition
Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
[No Abstract] [Full Text] [Related]
16. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis.
Mukherjee S; Chakraborty M; Ulmasov B; McCommis K; Zhang J; Carpenter D; Msengi EN; Haubner J; Guo C; Pike DP; Ghoshal S; Ford DA; Neuschwander-Tetri BA; Chakraborty A
Mol Metab; 2021 Dec; 54():101364. PubMed ID: 34757046
[TBL] [Abstract][Full Text] [Related]
17. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
18. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
Agosti P; Sabbà C; Mazzocca A
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
[TBL] [Abstract][Full Text] [Related]
19. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
[TBL] [Abstract][Full Text] [Related]
20. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
[No Abstract] [Full Text] [Related]
[Next] [New Search]
